High Sensitivity Cardiac Troponins: a Curse or a Blessing? by Manolis, Antonis S
High Sensitivity Cardiac Troponins:  
a Curse or a Blessing?
Antonis S. Manolis, MD
A B S T R A C T
The use of cardiac troponins (cTn) in lieu of creatine kinase to diagnose myocardial 
infarction (MI) has allowed us to detect even the smallest myocardial damage. Re-
cently the use of high-sensitivity assays to measure even the tiniest myocardial inju-
ries has led to a substantial increase in the diagnosis of MI. However, the specificity 
of such tests has been compromised and false positive results are rising. Clinicians 
should be aware that elevated cTn may be encountered in a variety of conditions of 
non-thrombotic cardiac damage, but also in a plethora of non-coronary diseases and 
laboratory interferences. These caveats are herein overviewed and an algorithm is 
proposed of a step-wise approach to using cTn measurement to triage and manage 
patients with suspected acute coronary syndromes.
Triage of patients with chest pain in the emergency departments in a timely fashion 
by identifying those with acute coronary syndromes (ACS) is crucial for delivery of 
appropriate medical or interventional therapy and avoidance of catastrophies.1,2 In ad-
dition to clinical, ECG and imaging data, use of an ideal biomarker would expedite the 
process of early diagnosis, risk stratification and management of such patients.1-4 The 
recent introduction of high-sensitivity cardiac troponin (cTn) I or T assays aspires to 
achieve just that, i.e. to provide greater accuracy for diagnosis of ACS, but the question 
remains how well these assays can implement this task.5,6 As the sensitivity of detecting 
cardiac troponin rises, the specificity declines and this poses several problems.7 The 
introduction of such highly sensitive assays can effectively identify cardiac troponins in 
almost all patients with chronic coronary artery disease,8 but also in healthy individu-
als, thus the major concern now remains how to define normal levels and establish 
clinically useful cutoffs. A higher threshold to diagnose myocardial infarction (MI) 
may be needed when using these newer assays.7 The current consensus criteria propose 
a typical rise and/or fall above the 99th percentile of the upper reference limit (URL) 
in cardiac troponins in addition to other symptoms and signs of ischemia for the 
diagnosis of acute MI.9 There may be an exception to the rise and fall pattern if the 
patient presents >24 hours after the onset of chest pain. Troponin values may remain 
elevated for up to 4-7 days for troponin I and 10–14 days for troponin T following the 
onset of MI.10 In addition to aiding the diagnosis, cardiac troponins are also useful for 
risk stratification;4,11 current guidelines recommend an early interventional approach 
in high-risk ACS patients as based on elevated cardiac troponin level.3
Although cardiac troponin is the most sensitive and specific biomarker of myo-
cardial injury, it does not necessarily mean that the cause of such injury is an acute 
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MI. Non-thrombotic myocardial tissue damage by a variety 
of mechanisms can raise cardiac troponin and a plethora of 
non-coronary conditions can also lead to troponin elevation 
(Table 1),12,13 but they usually lack the typical rise and fall 
pattern of an acute MI and the associated clinical, ECG and 
imaging criteria. Thus, an elevated troponin in the absence of 
clinical evidence of ischemia, should lead to a search for other 
etiologies of myocardial necrosis, such as acute perimyocardi-
tis, pulmonary embolism, aortic dissection, acute heart failure, 
renal failure or other non-ischemic conditions (Table 1).
According to the new definition of MI,9 only type 1 MI is 
due to a primary coronary event such as plaque erosion and/or 
rupture, fissuring, or dissection, while type 2 is due to either 
increased oxygen demand or decreased supply, e.g. coronary 
artery spasm, coronary embolism, anemia, arrhythmias, hy-
pertension, or hypotension. Both types of MI need to fulfill 
the criteria of troponin rise and fall pattern together with 
clinical, ECG and/or imaging evidence of ischemia. Conven-
tionally, for MI type 4a (post-PCI) and 4b (stent thrombosis), 
increases of troponin greater than 3 × 99th percentile URL 
have been designated as defining PCI-related MI. For type 5 
MI (post-cardiac surgery), increases of troponin greater than 
5 × 99th percentile URL plus either new pathological Q waves 
or new left bundle branch block (LBBB), or angiographically 
documented new graft or native coronary artery occlusion, or 
imaging evidence of new loss of viable myocardium have been 
designated as defining CABG-related MI.9
Acute and chronic heart failure is notorious for its as-
sociation with elevated levels of cardiac troponin, albeit at 
relatively low concentrations, which indicate an increased risk 
of morbidity and mortality in these patients, providing further 
prognostic information in addition to other conventional clini-
cal and laboratory variables.14 Again, the typical troponin rise 
and fall pattern of classical MI is contrasted with the persistent 
low-level elevation or gradual decline of troponin in heart 
failure, and, of course the chest pain and typical ECG changes 
TABlE 1. Causes of Elevated Cardiac Troponin Levels
Acute MI Critically ill patients
Coronary vasospasm Renal failure
Pulmonary edema or heart failure Strenuous exercise
Acute pericarditis Chemotherapy (adriamycin, cyclophosphamide, etc)
Myocarditis Left ventricular hypertrophy
Endocarditis Diabetes mellitus
Heart transplantation Post-operative noncardiac surgery
Cardiac trauma/Myocardial contusion Acute rheumatic fever
Post-cardiac surgery COPD exacerbation
Tako-tsubo cardiomyopathy (apical ballooning) Lobar pneumonia
Tachyarrhythmias Hypertensive emergency and hypertension (including gestational)
Radiofrequency catheter ablation Acute aortic dissection
Cardioversion and CPR Infiltrative diseases (amyloidosis, hemosiderosis, pompe’s dis., sarcoid disease, etc)
Sympathomimetic drugs Churg-Strauss vasculitis with eosinophilia
Pulmonary embolism Animal bites (scorpion, jellyfish)
ARDS Rhabdomyolysis
CVA/Intracerebral hemorrhage Sepsis
Epileptic seizures Extensive burns
Shock/Hypotension False positive cardiac troponin testing (interfering mechanisms: heterophile 
antibodies from –occupational- exposure to monoclonal mouse antibodies or 
domestic animals, rheumatoid factor, macroenzymes in autoimmune or liver 
diseases, immunotherapies, vaccinations, or blood transfusions, etc)
ARDS = acute respiratory distress syndrome; COPD = chronic obstructive pulmonary disease; CPR = cardiopulmonary resuscitation; CVA = 
cerebrovascular accident; MI = myocardial infarction
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are herein missing. Other clues include the common (in heart 
failure) vs the occasional (in MI) occurrence of shortness of 
breath, the respective rare vs usual CK-MB elevation and the 
common vs rare BNP elevation, features useful to differentiate 
heart failure from MI.
In order to more effectively implement the correct use of 
troponin in ruling in or out an acute MI, a step-wise approach 
is recommended and presented in an algorithm in Figure 1. 
Whatever the steps being taken, clinical judgment should su-
persede any laboratory assay for biomarkers.15 A most blatant 
clinical error would be to use troponin to exclude unstable 
angina. This is a clinical and ECG diagnosis and treatment 
should be started promptly without waiting for a troponin level, 
although some of these patients will eventually rule-in for non-
ST elevation MI (NSTEMI). Unfortunately, it is this group, 
the first troponin-negative NSTEMI patients, who receive less 
aggressive therapy and thus have higher chances of sustaining 
a recurrent MI during short-term follow-up.16 Emergency room 
* Do not use the troponin test to exclude unstable angina. To more safely rule out acute MI, document the time of onset of chest 
pain or at least the time of presentation to the emergency room in every patient. The sensitivity and negative predictive value of cTn 
is extremely high if measured at least 6 hours after the onset of chest pain.
** A rising troponin level is required to diagnose acute MI. In patients with baseline elevations of troponin (e.g. patients with chronic 
renal failure), two measurements are required to demonstrate a rising pattern. Troponin is considered negative when measured 
>6-9 hours after the onset of chest pain and ACS unlikely if no recurrent chest pain and no ECG changes. Troponin is specific for 
myocardial cell damage; however, the cause may be other than ACS (see Table 1).
*** if not rising, consider alternate etiology for elevated troponin
FiguRE 1. Algorithm for Management of Patients with Suspected ACS Using Cardiac Troponin. ACS = acute coronary syndrome 




physicians and cardiologists should not be reassured by the 
first normal troponin and patients with the clinical syndrome 
and the ECG changes should be treated aggressively without 
waiting for the result of the second troponin measurement. 
Similarly, patients presenting with a typical clinical syndrome 
and ECG changes of an ACS do not need to be delayed for the 
result of a cTn assay; they should be promptly managed with 
an aggressive pharmaceutical and interventional therapy. It is 
only in patients with a low likelihood of an ACS that one should 
rely on cTn measurements for management decisions (Fig. 1).
With regards to the two types of cardiac troponin, cTn I 
and cTn T, there seems to be concordance in the majority of 
cases; however, discordant values have been reported, and 
some investigators have proposed that it might be helpful to 
confirm clinically equivocal increases or results unexpectedly 
below the cutoff value, obtained for one cardiac troponin 
by measuring the other.17 A better approach remains with 
the clinician who should be relying on or guided by clinical 
judgment and use this high-sensitivity troponin conundrum 
to his/her own patients’ advantage by requesting a cTn assay 
only when clinically indicated and interpreting the results in 
the context of the clinical presentation at hand, resisting inap-
propriate requests and erroneous interpretations. Inevitably, 
the use of high-sensitivity troponin assays in the emergency 
room will lead to an increase of diagnosed MIs, particularly 
NSTEMI. High sensitivity assays disclose small elevations in 
circulating cTn and therefore detect MI earlier than tradi-
tional assays. Using the 99th percentile of URL as the cut-off 
value will probably maintain a balance between sensitivity 
and specificity; MI can be effectively ruled out within 3-4 
hours of onset of chest pain with a negative cTn, while repeat 
measurements will limit any initial false negative results and 
enhance the sensitivity for ruling in more MIs at a later time 
by documenting the typical rise and/or fall pattern of an MI, 
all, of course, in the appropriate clinical context. Even in those 
with initially elevated values, serial measurements will discern 
those with an MI (typical rise and/or fall pattern) from those 
with other etiologies for an elevated cTn (Table 1). For patients 
with intermediate or high clinical suspicion of ACS, cardiac 
troponins do not offer much help for deciding on therapeutic 
strategy, which should be aggressive from the start, without 
having to wait for the cTn result. On the other hand, in pa-
tients with low clinical suspicion of ACS, cTn assay could be 
crucial to guide further management steps as outlined in the 
proposed algorithm (Fig. 1).
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